Experimental drug aims to help people shed pounds in 44-Week trial
NCT ID NCT06703021
Summary
This study is testing whether a new medication called aleniglipron (GSBR-1290) can help adults with obesity or overweight lose weight when combined with diet and exercise. Researchers will compare the drug against a placebo in 82 participants over 44 weeks to see if it's safe and effective. The study focuses on people who have at least one additional weight-related health condition like high blood pressure or cholesterol.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ACCESS II Research Site
Glendale, California, 91206, United States
-
ACCESS II Research Site
Montclair, California, 91763, United States
-
ACCESS II Research Site
Valparaiso, Indiana, 46383, United States
-
ACCESS II Research Site
West Des Moines, Iowa, 50265, United States
-
ACCESS II Research Site
Medford, Oregon, 97504, United States
-
ACCESS II Research Site
East Greenwich, Rhode Island, 02818, United States
-
ACCESS II Research Site
North Charleston, South Carolina, 29405, United States
-
ACCESS II Research Site
Dallas, Texas, 75042, United States
-
ACCESS II Research Site
San Antonio, Texas, 78240, United States
-
ACCESS II Research Site
West Jordan, Utah, 84088, United States
Conditions
Explore the condition pages connected to this study.